125 related articles for article (PubMed ID: 37203199)
1. Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system.
Zhang L; Pan C; Yang X; Jiang D; Cao M
Expert Opin Drug Saf; 2024 Jun; 23(6):785-792. PubMed ID: 37203199
[TBL] [Abstract][Full Text] [Related]
2. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
3. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
[TBL] [Abstract][Full Text] [Related]
4. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
5. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
[TBL] [Abstract][Full Text] [Related]
6. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
Bonora BM; Raschi E; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2021 Feb; 20(1):39. PubMed ID: 33573667
[TBL] [Abstract][Full Text] [Related]
7. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors.
Alkabbani W; Gamble JM
Br J Clin Pharmacol; 2023 Feb; 89(2):431-439. PubMed ID: 34964156
[TBL] [Abstract][Full Text] [Related]
8. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
Cao M; Pan C; Tian Y; Wang L; Zhao Z; Zhu B
Int J Clin Pharm; 2023 Jun; 45(3):689-697. PubMed ID: 36977858
[TBL] [Abstract][Full Text] [Related]
10. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
11. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials.
Muhammed A; Thomas C; Kalaiselvan V; Undela K
Expert Opin Drug Saf; 2024 Jun; 23(6):731-742. PubMed ID: 37986140
[TBL] [Abstract][Full Text] [Related]
12. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥ 75 years): a retrospective, pharmacovigilance study.
Goldman A; Fishman B; Twig G; Raschi E; Cukierman-Yaffe T; Moshkovits Y; Pomerantz A; Ben-Zvi I; Dankner R; Maor E
Cardiovasc Diabetol; 2023 Jan; 22(1):16. PubMed ID: 36694178
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Baksh SN; McAdams-DeMarco M; Segal JB; Alexander GC
Pharmacoepidemiol Drug Saf; 2018 Jun; 27(6):660-667. PubMed ID: 29655237
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system.
Nicholls C; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805
[TBL] [Abstract][Full Text] [Related]
15. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors.
Fadini GP; Sarangdhar M; De Ponti F; Avogaro A; Raschi E
BMJ Open Diabetes Res Care; 2019; 7(1):e000725. PubMed ID: 31641524
[TBL] [Abstract][Full Text] [Related]
17. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
18. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
19. Do sodium-glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real-world study.
Zhao B; Shen J; Zhao J; Pan H
J Diabetes Investig; 2021 Aug; 12(8):1400-1407. PubMed ID: 33325646
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
Palapra H; Viswam SK; Kalaiselvan V; Undela K
Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
